Gossamer Bio CEO Faheem Hasnain at BIO22 (J.T. MacMillan Photography)
March 17, 2023 10:18 AM EDT
R&D

Gos­samer stops en­roll­ment on BTK in­hibitor pro­gram, goes all in on PAH drug

Lei Lei Wu

News Reporter

Gos­samer Bio is stop­ping en­roll­ment on a Phase Ib/II tri­al of its BTK in­hibitor in CNS lym­phoma, it said in its

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times